Athira Pharma

Athira Pharma 是一家在股票代码 ATHA (US) 下上市的公司。

查看带有其 17 名主要高管的组织结构图

Athira Pharma 搜索最多的简介

• Mark Litton, President and Chief Executive Officer
• John Fluke, Director
• James Johnson, Director

高管在Athira Pharma变化

• Javier San Martin已作为Chief Medical Officer加入公司  (新闻发布的2024四月16号).
• Hans Moebius, Chief Medical Officer, 已经离开公司  (新闻发布的2024四月16号).

创建提醒
跟踪 Athira Pharma 的高管变动

Athira Pharma 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Stemtech and Seacret Direct have announced they will merge  (公布2024十二月5号)..
• Recursion Pharma and Exscientia have merged  (公布2024十一月27号)..
• Stemtech and Seacret Direct have announced they will merge  (公布2024十一月22号)..

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board

了解更多有关药店行业的信息 >

Athira Pharma 的最新新闻稿

• Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND | Athira Pharma
• Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | Athira Pharma
• Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting | Athira Pharma
• Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | Athira Pharma
• Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease | Athira Pharma
• Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024 | Athira Pharma
• Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates | Athira Pharma
• Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease | Athira Pharma
• Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) | Athira Pharma
• Athira Pharma to Participate in Upcoming June Conferences | Athira Pharma
• View more press releases Close

关于 Athira Pharma 的社交媒体

• Athira Pharma 在 维基百科、谷歌新闻 和 雅虎财经
• Athira Pharma 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Mark Litton

致电Athira Pharma，电话：+1 98...

查看组织结构图

Register to receive your alert

报告错误